ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2246

Real World Experience with Belimumab in the Management of Systemic Lupus Erythematosus (SLE): A Single Center, Observational, Post-Marketing Study

Susan S. Kim1, Tanya Pavri1, Kyriakos A. Kirou2, Jane Salmon1 and Doruk Erkan1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: belimumab and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:  With the recent FDA approval of belimumab, clinicians are faced with adjusting their SLE treatment paradigm. The purpose of this study was to examine the patterns of belimumab use, as well as its tolerability and efficacy in a “real world” tertiary clinical setting.

Methods:  We identified belimumab-receiving patients from our SLE Registry. We retrieved the demographics, belimumab indications, medications, ACR SLE criteria, SELENA-SLEDAI and SLICC scores, and PGA from the registry; we performed a focused infusion chart review for prophylactic-medications (acetaminophen and diphenhydramine) and infusion reactions (during or within 24 hours of the infusion). We analyzed the baseline and 3-6-9 month data in a descriptive fashion by stratifying based on baseline SELENA-SLEDAI scores (0, 1-5, ≥6), PGA scores (0-1.49, 1.5-2, 3), and prednisone dose (≤ 7.5, >7.5 mg).

Results:  23 patients (female: 21; mean age 38.3±12y; mean disease duration: 11.9±7.0y; mean SLICC score: 1.3±1.3) received 134 belimumab infusions (range: 1-11) between 8/11 and 6/12. All patients except one fulfilled the ACR SLE Classification Criteria; all patients were seropositive (ANA [83%] or anti-dsDNA [57%]). Indications for belimumab were active mucocutaneous disease (MC) (3), active musculoskeletal disease (MSK) (10), active MC+MSK (3), CNS lupus under remission but requiring high dose corticosteroids (CS) (2), active serositis (1), active skin ulcers (1), cutaneous vasculitis (1), cryoglobulinemia/cytopenia (1), and gastrointestinal vasculitis (1). Concomitant medications were CS 19 (83%), hydroxychloroquine 18 (78%), azathioprine 4 (17%), mycophenolate mofetil 6 (26%), and methotrexate 1 (4%). Prophylactic-medications were given to 13 (56%) patients prior to infusions; 4 (17%) experienced transient infusion reactions (itching: 1, urticarial rash: 1, headache: 1, and URI/diarrhea: 1). Table demonstrates the baseline and follow-up SELENA-SLEDAI, PGA, CS dose, dsDNA, and C3/4. One (4%) patient discontinued the medication due to lack of clinical efficacy after 2 doses. Two (8%) patients have postponed the treatment after 3 months due to hospitalizations for unrelated events (MI, MVA).

Mean±SD (#)

BL (n:23)

3-month (n:12)

6-month (n:5)

9-month (n:4)

SELENA-SLEDAI

 

 

 

 

– BL: 0*

0 (3)

0 (2)

–

–

– BL: 1-5

3.50±1.08 (10)

3.33±1.15 (3)

–

–

– BL: ≥6

8.60±2.50 (10)

5.86±3.29 (7)

5.20±2.28 (5)**

5.50±1.91 (4)

PGA

 

 

 

 

– Entire Group

0.92±0.69 (23)

0.55±0.47 (12)

0.54±0.45 (5)

0.75±0.65 (4)

– BL: 0-1.49

0.61±0.48 (17)

0.52±0.53 (9)

0.75±0.78 (2)

0.75±1.06 (2)

– BL: 1.5-3

1.78±0.36 (6)

0.66±0.29 (3)

0.40±0.17 (3)

0.75±0.35 (2)

Prednisone Dose

 

 

 

 

– BL: ≤ 7.5mg

2.86±3.39 (8)

4.30±2.91 (5)

10 (1)

10 (1)

– BL: > 7.5 mg

13.17±4.06 (15)

10.71±4.50 (7)

10.00±4.08 (4)

7.92±2.60 (3)

dsDNA (+) (n/n+)

10/15 (67%)

5/10 (50%)

1/3 (33%)

0/1 (0%)

C3 Abnormal (n/n+)

9/17 (53%)

3/10 (30%)

1/3 (33%)

0/1 (0%)

C4 Abnormal (n/n+)

11/17 (65%)

6/10 (60%)

1/3 (33%)

0/1 (0%)

BL: baseline; n/n+: total # of patients with positive test/total # of patients in which the test result was available. *No disease activity at BL but history of difficulty in CS tapering; mean prednisone doses were 15.8±7.2 mg and 6.25±1.7mg at BL and 3m, respectively. **5 patients who completed 6m follow-up had SLEDAI scores of 9.20±2.68, 4.40±2.61, and 5.20±2.28, at BL, 3m, and 6m, respectively.

Conclusion:  Our study completed in a tertiary care “real world” setting demonstrates that: a) belimumab use is not limited to patients with SELENA-SLEDAI≥6; b) infusion reaction rate is comparable to clinical trial data; and c) despite relatively small number of patients and short duration of follow-up, the results are suggestive of improved disease activity.


Disclosure:

S. S. Kim,
None;

T. Pavri,
None;

K. A. Kirou,
None;

J. Salmon,
None;

D. Erkan,

Human Genome Sciences, Inc.,

8.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-experience-with-belimumab-in-the-management-of-systemic-lupus-erythematosus-sle-a-single-center-observational-post-marketing-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology